Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

Hemogenyx Pharmaceuticals (LSE:HEMO / OTC:HOPHF) announced its total issued share capital and voting rights as of 27 February 2026.

Rhea-AI Summary

Hemogenyx Pharmaceuticals (LSE:HEMO / OTC:HOPHF) announced its total issued share capital and voting rights as of 27 February 2026. The Company reported 6,425,429 ordinary shares, none held in treasury, so the total voting rights equal 6,425,429.

Shareholders may use this figure as the denominator to assess FCA Disclosure Guidance and Transparency Rules notification obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON, UK / ACCESS Newswire / February 27, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 27 February 2026 consists of6,425,429ordinary shares of 1p each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 6,425,429.

The figure of 6,425,429 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
AlbR Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.

The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are Hemogenyx (HOPHF) total voting rights as of 27 February 2026?

Hemogenyx (HOPHF) has 6,425,429 voting rights as of 27 February 2026, with no shares held in treasury. According to the company, this figure is the official denominator for calculating whether shareholders must notify changes under FCA Disclosure Guidance and Transparency Rules.

How should Hemogenyx (HOPHF) shareholders use the 6,425,429 figure for FCA notification thresholds?

Shareholders should use 6,425,429 as the denominator to calculate percentage holdings for FCA thresholds. According to the company, this ensures accurate assessment of whether a transaction or holding reaches mandatory disclosure levels under FCA rules.

Will the Hemogenyx (HOPHF) total voting rights number change and how will investors be informed?

The total voting rights can change with share issues, buybacks, or treasury movements; investors are informed by company announcements. According to the company, any future changes will be published as regulatory notices to update the official denominator.

Where can investors verify Hemogenyx (HOPHF) share capital and contact the company for enquiries?

Investors can verify share capital via the company's regulatory announcements and investor contacts listed in the notice. According to the company, investor enquiries may be directed to the provided corporate contacts and investor relations channels.

Does the 6,425,429 voting rights figure affect Hemogenyx (HOPHF) dividend or voting procedures?

The figure defines the total voting rights and is used for calculating shareholder percentages but does not itself change dividends or procedures. According to the company, dividend and voting mechanics remain governed by corporate bylaws and separate disclosures.